Privately insured Americans under 65 who are diagnosed with cancer face steep out-of-pocket costs—averaging nearly $600 more per month than peers without cancer—and those costs climb sharply with disease stage. A JAMA Network Open study tracking more than 46,000 individuals reveals that patients with stage 4 cancer paid over $700 a month during the first six months after diagnosis, exposing financial gaps even among those with insurance.
Higher cancer stage, higher patient cost
Researchers linked private insurance claims with cancer registry data from the SEER program to track real patient spending. They found that out-of-pocket costs (OOPCs)—including deductibles, copays, and coinsurance—rose significantly after a diagnosis of breast, colorectal, or lung cancer.
On average, patients with cancer paid $592.53 more per month than similar individuals without cancer. But for those with late-stage cancer, the financial hit was worse:
- Stage 0: $462/month increase
- Stage II: $661/month increase
- Stage IV: $720/month increase
The authors used a difference-in-differences method to control for baseline spending trends, making it one of the first studies to isolate the direct financial burden of cancer treatment in the privately insured population.
Financial stress begins before treatment starts
Costs began rising the month of diagnosis and stayed elevated for six months, regardless of cancer type. For some patients, these expenses totaled more than $4,000 during the initial treatment period. Importantly, the study excluded patients over 65, who typically have Medicare, focusing instead on younger adults navigating employer-sponsored insurance.
Why stage matters—and why it hasn’t been measured until now
Though it may seem obvious that later-stage cancer would cost more to treat, this study is the first to quantify that connection using high-quality staging data linked to real insurance claims.
“This result has not previously been empirically demonstrated, to our knowledge,” the authors wrote.
That’s in part because private insurance datasets rarely include clinical cancer stage. By integrating claims with SEER registry data, this study overcame that barrier—offering new insights into how disease progression affects patient finances.
Policy implications beyond the numbers
The authors warn that high OOPCs can trigger “financial toxicity”—a term for the economic strain that can lead patients to delay or abandon care. Because most Americans under 65 rely on employer-based insurance, a cancer diagnosis can threaten both health and job security.
For policymakers and employers, the findings point to several urgent needs:
- Expand paid sick leave to preserve insurance coverage during treatment
- Offer early screening to catch cancers before they advance
- Design insurance plans that minimize upfront cost burden for serious illness
With cancer rates rising among younger adults, understanding—and addressing—the economic burden of care is no longer a Medicare-only issue.
Journal: JAMA Network Open
DOI: 10.1001/jamanetworkopen.2025.21575
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.